These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 8834170)

  • 1. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
    Pollock PM; Pearson JV; Hayward NK
    Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
    Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
    Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
    Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
    Oncogene; 1995 Mar; 10(6):1061-7. PubMed ID: 7700630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
    Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
    Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
    Yoshida S; Todoroki T; Ichikawa Y; Hanai S; Suzuki H; Hori M; Fukao K; Miwa M; Uchida K
    Cancer Res; 1995 Jul; 55(13):2756-60. PubMed ID: 7796400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines.
    Pollock PM; Yu F; Qiu L; Parsons PG; Hayward NK
    Oncogene; 1995 Aug; 11(4):663-8. PubMed ID: 7651729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
    Brenner AJ; Aldaz CM
    Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.
    Caldas C; Hahn SA; da Costa LT; Redston MS; Schutte M; Seymour AB; Weinstein CL; Hruban RH; Yeo CJ; Kern SE
    Nat Genet; 1994 Sep; 8(1):27-32. PubMed ID: 7726912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
    Spanakis NE; Gorgoulis V; Mariatos G; Zacharatos P; Kotsinas A; Garinis G; Trigidou R; Karameris A; Tsimara-Papastamatiou H; Kouloukousa M; Manolis EN; Kittas C
    Anticancer Res; 1999; 19(3A):1893-9. PubMed ID: 10470133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
    J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene.
    Wiest JS; Franklin WA; Otstot JT; Forbey K; Varella-Garcia M; Rao K; Drabkin H; Gemmill R; Ahrent S; Sidransky D; Saccomanno G; Fountain JW; Anderson MW
    Cancer Res; 1997 Jan; 57(1):1-6. PubMed ID: 8988029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
    Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
    Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
    Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
    Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
    Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
    Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
    Gazzeri S; Gouyer V; Vour'ch C; Brambilla C; Brambilla E
    Oncogene; 1998 Jan; 16(4):497-504. PubMed ID: 9484839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
    Kamb A; Shattuck-Eidens D; Eeles R; Liu Q; Gruis NA; Ding W; Hussey C; Tran T; Miki Y; Weaver-Feldhaus J
    Nat Genet; 1994 Sep; 8(1):23-6. PubMed ID: 7987388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis.
    Luca M; Xie S; Gutman M; Huang S; Bar-Eli M
    Oncogene; 1995 Oct; 11(7):1399-402. PubMed ID: 7478563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient.
    Glendening JM; Flores JF; Walker GJ; Stone S; Albino AP; Fountain JW
    Cancer Res; 1995 Dec; 55(23):5531-5. PubMed ID: 7585628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).
    Schmid M; Malicki D; Nobori T; Rosenbach MD; Campbell K; Carson DA; Carrera CJ
    Oncogene; 1998 Nov; 17(20):2669-75. PubMed ID: 9840931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.